Wells Fargo & Company MN Lowers Stock Holdings in AC Immune SA (NASDAQ:ACIU)

Wells Fargo & Company MN reduced its holdings in AC Immune SA (NASDAQ:ACIU) by 10.1% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 995,636 shares of the company’s stock after selling 112,402 shares during the quarter. Wells Fargo & Company MN owned approximately 1.01% of AC Immune worth $2,688,000 as of its most recent filing with the Securities and Exchange Commission.

Separately, RPO LLC acquired a new position in shares of AC Immune during the 4th quarter valued at about $51,000. Hedge funds and other institutional investors own 51.36% of the company’s stock.

Wall Street Analyst Weigh In

Separately, HC Wainwright reissued a “buy” rating and issued a $16.00 target price on shares of AC Immune in a research report on Thursday, April 3rd.

AC Immune Trading Up 5.1 %

Shares of AC Immune stock opened at $1.66 on Friday. The business’s fifty day moving average price is $2.03 and its 200 day moving average price is $2.64. AC Immune SA has a twelve month low of $1.43 and a twelve month high of $4.98. The stock has a market capitalization of $166.68 million, a P/E ratio of -3.61 and a beta of 1.49.

About AC Immune

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.